DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

DHR·Danaher Corporation

$.
+. (+.%)
After Hours
High
$176.59
Open
$173.81
Market Cap
122.31B
52W High
$242.80
Low
$171.60
P. Close
$173.21
P/E
33.16
52W Low
$160.93
Fwd P/E
94.40
Mean Target
$246.30
Technical Score (1D)
27
SELL
News Sentiment
72
BULLISH
Danaher (DHR) recently exceeded Q1 earnings expectations and raised its full-year guidance, signaling strong performance driven by its Biotechnology segment which saw 7% core revenue growth. This positive outlook is further bolstered by advancements in innovation, including AI platforms and carbon-capture filtration, alongside progress on the pending Masimo acquisition. The acquisition of Masimo for $9.9 billion is on track for a second-half closing, pending regulatory approval, with Masimo's Q1 results indicating operational stability. Institutional investors continue to show interest, with Pinnbrook Capital Management LP initiating a new position. Meanwhile, Danaher's subsidiaries are strategically investing in growth areas: Pall Corporation is piloting advanced filtration for carbon capture with government funding, and Genedata launched an AI-native CMC solution for biopharma. These developments highlight Danaher's focus on climate technology and life sciences software. Looking ahead, investors will monitor the execution of the Masimo acquisition and the adoption rates of its new technological innovations.
Earnings Summary
Danaher Corporation is a global manufacturer and marketer of diverse products and services across the Biotechnology, Life Sciences, and Diagnostics segments, operating within the Healthcare sector. The company provides essential tools and solutions for professional, medical, and industrial applications, with a focus on bioprocessing, scientific research, and clinical diagnostics. Danaher's business model is designed to serve critical needs in healthcare and life sciences, positioning it as a key player in these dynamic industries. In its most recent reported quarters, DHR demonstrated an upward trend in both earnings per share (EPS) and revenue. For Q1 2026, the company reported an actual EPS of $2.06 against an estimate of $1.86, and revenue of $5.95 billion against an estimate of $6.13 billion. This followed Q4 2025, where actual EPS was $2.23 on revenue of $6.84 billion, exceeding the estimated EPS of $2.17 and slightly missing revenue estimates of $6.87 billion. Comparing these to the prior two quarters, Q2 2025 saw actual EPS of $1.80 against an estimate of $1.64, with revenue at $5.94 billion, and Q3 2025 reported actual EPS of $1.89 against an estimate of $1.72, with revenue at $6.05 billion. This indicates a general pattern of EPS beats in recent quarters, with revenue performance showing some variability against estimates. Historically, Danaher has shown a trajectory of year-over-year growth, often beating analyst estimates for earnings per share. For instance, the company beat EPS estimates in Q1 2025, Q3 2025, and Q4 2025, and Q1 2026, demonstrating a consistent ability to exceed profit expectations. While revenue estimates were not consistently provided for all historical quarters, the recent trend suggests revenue growth alongside these EPS beats. Recent news highlights Danaher's strong operational performance, including exceeding Q1 earnings expectations and raising full-year guidance, driven by robust 7% core revenue growth in its Biotechnology segment. The company is also advancing its significant Masimo acquisition, expected to close in the second half of the year pending regulatory approval. Furthermore, strategic investments are being made in growth areas, such as Pall Corporation's pilot program for carbon capture filtration technology and Genedata's launch of an AI-native CMC solution for biopharma. Investors will be watching for the successful integration of the Masimo acquisition and the market adoption of its new AI and carbon-capture technologies as key indicators of future performance. The company's ability to navigate regulatory approvals for acquisitions and the commercial success of its innovative product launches will be critical watch points for the upcoming quarters.

EPS

EstBeatMiss
$1.56$1.75$1.94$2.13$2.32Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.83 - -
Q1'26$1.86$2.06+11.0%
Q4'25$2.17$2.23+2.6%
Q3'25$1.72$1.89+9.8%
Q2'25$1.64$1.80+9.5%
Q1'25$1.64$1.88+14.4%

Revenue

EstBeatMiss
$5.6B$5.9B$6.3B$6.7B$7.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.2B - -
Q1'26$6.1B$6.0B-2.9%
Q4'25$6.9B$6.8B-0.5%
Q3'25 - $6.1B -
Q2'25 - $5.9B -
Q1'25 - $5.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DHR Stock Snapshot

DHR is currently trading at $174.94, giving Danaher Corporation a market cap of 122.31B and a P/E ratio of 33.2. Today's range spans $171.60–$176.59, with shares opening at $173.81 and moving up $1.73 (1.0%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 72/100.

Over the past year DHR has traded between $160.93 and $242.80 - the current price is +8.7% off the 52-week low and -27.9% from the high. 32 analysts cover the stock with a Buy consensus and a mean 12-month target of $246.30 (range $200.00–$310.00), implying upside of +40.8%.

The path of least resistance for Danaher Corporation (DHR) is currently lower - 27/100 (SELL), bullish sentiment (72/100), price $174.94 (near 52-week lows within $160.93–$242.80). The current P/E ratio stands at 33.2. At 122.31B in Healthcare market cap, this large-cap name is in the zone where portfolio risk managers - not just traders - are making decisions. Trimming positions on technical deterioration is standard practice at this size, and the current setup gives them a clear rationale to act.

When a large-cap Healthcare name with 122.31B in capitalization prints a SELL signal (27/100) alongside bullish news sentiment (72/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $174.94 (near 52-week lows in the $160.93–$242.80 range), the structural support levels are where that sponsorship question gets answered.